Overview

Apremilast for Alcohol Use Disorder Treatment in Women and Men

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-02-28
Target enrollment:
Participant gender:
Summary
For this protocol, the investigators plan to collect pilot data to evaluate apremilast (60mg/day) in adults with Alcohol Use Disorders (AUD).
Phase:
PHASE1
Details
Lead Sponsor:
Yale University
Collaborators:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Office of Research on Women's Health (ORWH)
Treatments:
apremilast